 Imidazoles
"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 3 | 1 | 4 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 5 | 5 | | 1999 | 1 | 3 | 4 | | 2000 | 5 | 3 | 8 | | 2001 | 2 | 7 | 9 | | 2002 | 3 | 8 | 11 | | 2003 | 3 | 4 | 7 | | 2004 | 0 | 2 | 2 | | 2005 | 4 | 2 | 6 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 3 | 4 | | 2009 | 3 | 2 | 5 | | 2010 | 3 | 7 | 10 | | 2011 | 2 | 3 | 5 | | 2012 | 4 | 5 | 9 | | 2013 | 4 | 5 | 9 | | 2014 | 3 | 6 | 9 | | 2015 | 7 | 8 | 15 | | 2016 | 3 | 3 | 6 | | 2017 | 4 | 5 | 9 | | 2018 | 4 | 3 | 7 | | 2019 | 3 | 0 | 3 | | 2020 | 3 | 3 | 6 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Rubin JD, Stanley JT, Sigauke RF, Levandowski CB, Maas ZL, Westfall J, Taatjes DJ, Dowell RD. Transcription factor enrichment analysis (TFEA) quantifies the activity of multiple transcription factors from a single experiment. Commun Biol. 2021 06 02; 4(1):661.
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
-
Alzofon N, Jimeno A. Capmatinib for non-small cell lung cancer. Drugs Today (Barc). 2021 Jan; 57(1):17-25.
-
Kondapalli L, Worth S, Hawi R, Vachhani P, Arora G, Bhatia R, Lenneman CG. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Vasc Med. 2020 06; 25(3):246-254.
-
Rizzotto D, Zaccara S, Rossi A, Galbraith MD, Andrysik Z, Pandey A, Sullivan KD, Quattrone A, Espinosa JM, Dassi E, Inga A. Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30. Cell Rep. 2020 03 31; 30(13):4355-4369.e6.
-
Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jürgensmeier JM, Fegan CD. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 06 15; 26(12):2810-2818.
-
Dimou A, Barron G, Merrick DT, Kolfenbach J, Doebele RC. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. BMC Cancer. 2020 Mar 04; 20(1):177.
-
Rizzi A, Jensen T, Slochower DR, Aldeghi M, Gapsys V, Ntekoumes D, Bosisio S, Papadourakis M, Henriksen NM, de Groot BL, Cournia Z, Dickson A, Michel J, Gilson MK, Shirts MR, Mobley DL, Chodera JD. The SAMPL6 SAMPLing challenge: assessing the reliability and efficiency of binding free energy calculations. J Comput Aided Mol Des. 2020 05; 34(5):601-633.
-
Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020 04; 189(2):363-368.
-
Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia. 2020 05; 34(5):1458-1461.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|